Los Feliz Healthcare Center: Insulin, Hygiene Lapses - CA
LOS ANGELES, CA - Federal inspectors documented significant medication safety failures and hygiene deficiencies at Los Feliz Healthcare & Wellness Center during a June 2024 inspection, finding that multiple diabetic residents received improper insulin administration that violated established medical protocols.
Medication Safety Violations Put Diabetic Residents at Risk
The most serious violations involved the facility's failure to properly administer insulin to three diabetic residents, creating potential for serious medical complications. Federal regulations require nursing homes to follow physician orders precisely, particularly for high-risk medications like insulin that can cause dangerous blood sugar fluctuations.
Improper Insulin Site Rotation Documented Across Multiple Residents
Inspectors found that nursing staff repeatedly failed to rotate insulin injection sites as ordered for residents receiving multiple daily insulin doses. The violations affected Resident 7, who had been admitted in January 2024 with type 2 diabetes, diabetic kidney disease, and diabetic nerve damage. Medical records showed that between April and June 2024, nursing staff administered insulin injections in the same body locations repeatedly, rather than following the physician's specific order to "rotate injection sites."
Documentation revealed concerning patterns of repeated injections in identical locations. For example, on April 25-26, 2024, Resident 7 received six separate insulin injections, with four administered in the exact same arm locations within a 24-hour period. Similar patterns occurred with Residents 118 and 109, who received multiple consecutive injections in the same abdominal quadrants without proper site rotation.
Medical Risks of Improper Insulin Administration
Proper insulin site rotation represents a fundamental safety practice in diabetes management. When insulin is repeatedly injected in the same location, it can cause lipodystrophy - a condition where fat tissue under the skin either breaks down or builds up abnormally. This creates hard lumps or depressions that not only affect appearance but significantly impact insulin absorption.
When insulin absorption becomes unpredictable due to tissue damage, residents face increased risk of both dangerously high and low blood sugar levels. High blood sugar (hyperglycemia) can lead to serious complications including diabetic ketoacidosis, while low blood sugar (hypoglycemia) can cause confusion, falls, unconsciousness, and potentially life-threatening medical emergencies.
The facility's own nursing staff acknowledged these risks during inspector interviews. A registered nurse told inspectors that "insulin administration sites should be rotated to prevent lipodystrophy and bruising and hardening of the tissues." The Director of Nursing confirmed that "it is important to rotate insulin administration sites to prevent phlebitis (inflammation of a vein) and lipodystrophy."
Industry Standards Clearly Define Proper Injection Protocols
Professional medical standards and manufacturer guidelines explicitly require injection site rotation for all insulin products. The FDA-approved prescribing information for the specific insulin medications used at the facility clearly states requirements to "rotate injection sites within the same region for one injection to the next to reduce risk of lipodystrophy and localized cutaneous amyloidosis."
Standard diabetes care protocols recommend rotating between different areas of the body - typically the abdomen, thighs, upper arms, and buttocks - and then rotating within each area to allow tissue recovery between injections. For residents receiving multiple daily insulin doses, as these residents were, proper rotation becomes even more critical to prevent tissue damage.
The facility had access to detailed manufacturer guidelines for each insulin product. Documentation showed they had prescribing information stating that injection sites should be rotated "within an injection area (abdomen, thigh, or deltoid) to reduce the risk of lipodystrophy" and "to rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis."